NK Cells(Xinxiang Medical University)(NK Cells(Xinxiang Medical University)) - 在研适应症：新型冠状病毒感染_专利_临床

概要

基本信息

药物类型

自然杀伤细胞疗法

别名-

靶点-

作用机制

免疫细胞毒性

治疗领域

感染呼吸系统疾病

在研适应症

新型冠状病毒感染

非在研适应症-

原研机构

新乡医学院

在研机构

新乡医学院

非在研机构-

最高研发阶段临床1期

首次获批日期-

最高研发阶段(中国)临床1期

特殊审评-

登录后查看时间轴

关联

1

项与 NK Cells(Xinxiang Medical University) 相关的临床试验

NCT04280224

/ Completed临床1期IIT

Clinical Investigation of Natural Killer Cells Treatment in Pneumonia Patients Infected With 2019 Novel Coronavirus

Since december 2019, acute respiratory disease due to 2019 novel coronavirus (2019-nCoV) emerged in Wuhan city and rapidly spread throughout China. There is no confirmed antivirus therapy for 2019-nCoV infection. Natural killer (NK) cells are innate lymphocytes that may serve as useful effectors against danger infection. The purpose of this clinical investigation is to evaluate the safety and efficiency of NK Cells in combination with standard therapy for pneumonia patients infected with 2019-nCoV.

开始日期2020-02-15

申办/合作机构